Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

Iron overload in myelodysplastic syndromes: Evidence based guidelines from the Canadian consortium on MDS.

Leitch HA, Buckstein R, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Shamy A, Elemary M, Wells RA.

Leuk Res. 2018 Sep 19;74:21-41. doi: 10.1016/j.leukres.2018.09.005. [Epub ahead of print] Review.

PMID:
30286330
2.

Defining clinically relevant measures of iron overload around haemopoietic stem cell transplantation.

Leitch HA.

Lancet Haematol. 2018 May;5(5):e184-e185. doi: 10.1016/S2352-3026(18)30033-4. Epub 2018 Apr 5. No abstract available.

PMID:
29628398
4.

Iron chelation therapy in lower IPSS risk myelodysplastic syndromes; which subtypes benefit?

Wong SA, Leitch HA.

Leuk Res. 2018 Jan;64:24-29. doi: 10.1016/j.leukres.2017.11.005. Epub 2017 Nov 11.

PMID:
29149650
5.

Castleman disease: delineating the spectrum.

Alzahrani M, Leitch HA.

Br J Haematol. 2018 Jan;180(2):173-174. doi: 10.1111/bjh.15016. Epub 2017 Nov 16. No abstract available.

PMID:
29143317
6.

Frequency of and reasons for paroxysmal nocturnal haemoglobinuria screening in patients with unexplained anaemia.

England JT, Dalal B, Leitch HA.

J Clin Pathol. 2018 Apr;71(4):364-367. doi: 10.1136/jclinpath-2017-204724. Epub 2017 Nov 14.

PMID:
29138283
7.

A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry.

Houston BL, Jayakar J, Wells RA, Lenis M, Zhang L, Zhu N, Leitch HA, Nevill TJ, Yee KWL, Leber B, Sabloff M, St-Hilaire E, Kumar R, Geddes M, Shamy A, Storring JM, Keating MM, Elemary M, Delage R, Mamedov A, Buckstein R.

Ann Hematol. 2017 Dec;96(12):2025-2029. doi: 10.1007/s00277-017-3137-0. Epub 2017 Oct 3.

PMID:
28975386
8.

Chronic lymphocytic leukemia in a patient with well-controlled HIV infection: successful treatment with ibrutinib.

England JT, Leitch HA.

Leuk Lymphoma. 2018 Mar;59(3):752-754. doi: 10.1080/10428194.2017.1349904. Epub 2017 Jul 21. No abstract available.

PMID:
28728450
9.

Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating MM, Sabloff M, St Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R.

Br J Haematol. 2017 Oct;179(1):83-97. doi: 10.1111/bjh.14825. Epub 2017 Jul 5.

PMID:
28677895
10.

Toxicity of iron overload and iron overload reduction in the setting of hematopoietic stem cell transplantation for hematologic malignancies.

Leitch HA, Fibach E, Rachmilewitz E.

Crit Rev Oncol Hematol. 2017 May;113:156-170. doi: 10.1016/j.critrevonc.2017.03.002. Epub 2017 Mar 14. Review.

PMID:
28427505
11.

Autoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.

Williamson BT, Foltz L, Leitch HA.

Hematol Rep. 2016 May 10;8(2):6480. doi: 10.4081/hr.2016.6480. eCollection 2016 May 10.

12.

Practical Management of Castleman's Disease.

Alzahrani MF, Radwi M, Leitch HA.

Acta Haematol. 2016;136(1):16-22. doi: 10.1159/000444515. Epub 2016 Apr 29.

PMID:
27160307
13.

Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study.

Buckstein R, Wells RA, Zhu N, Leitch HA, Nevill TJ, Yee KW, Leber B, Sabloff M, St Hilaire E, Kumar R, Geddes M, Shamy A, Storring J, Kew A, Elemary M, Levitt M, Lenis M, Mamedov A, Zhang L, Rockwood K, Alibhai SM.

Br J Haematol. 2016 Jul;174(1):88-101. doi: 10.1111/bjh.14033. Epub 2016 Mar 15.

PMID:
26991631
14.

Pre- and post-treatment serum ferritin levels in patients with higher risk myelodysplastic syndromes receiving azacitidine.

Tsang E, Leitch HA.

Leuk Lymphoma. 2016 Nov;57(11):2709-11. doi: 10.3109/10428194.2016.1157878. Epub 2016 Mar 16. No abstract available.

PMID:
26980175
15.

Higher Risk Myelodysplastic Syndromes in Patients with Well-Controlled HIV Infection: Clinical Features, Treatment, and Outcome.

Williamson BT, Leitch HA.

Case Rep Hematol. 2016;2016:8502641. doi: 10.1155/2016/8502641. Epub 2016 Jan 20.

16.

Hematologic improvement with iron chelation therapy in acquired anemias.

Leitch HA.

Eur J Haematol. 2016 Jun;96(6):551-2. doi: 10.1111/ejh.12703. No abstract available.

PMID:
26572777
17.

Can iron overload in patients with lower-risk myelodysplastic syndromes be reduced using erythropoiesis-stimulating agents?

Tsang E, Leitch HA.

Ann Hematol. 2016 Jan;95(1):73-8. doi: 10.1007/s00277-015-2519-4. Epub 2015 Oct 10.

PMID:
26453076
18.

Durable Red Blood Cell Transfusion Independence in a Patient with an MDS/MPN Overlap Syndrome Following Discontinuation of Iron Chelation Therapy.

Kochhar H, Leger CS, Leitch HA.

Case Rep Hematol. 2015;2015:253294. doi: 10.1155/2015/253294. Epub 2015 Mar 30.

19.

Human immunodeficiency virus-associated multicentric Castleman disease refractory to antiretroviral therapy: clinical features, treatment and outcome.

Alzahrani M, Hull MC, Sherlock C, Griswold D, Leger CS, Leitch HA.

Leuk Lymphoma. 2015 May;56(5):1246-51. doi: 10.3109/10428194.2014.935368. Epub 2014 Aug 20.

PMID:
25093377
20.

Design of long circulating nontoxic dendritic polymers for the removal of iron in vivo.

Imran ul-haq M, Hamilton JL, Lai BF, Shenoi RA, Horte S, Constantinescu I, Leitch HA, Kizhakkedathu JN.

ACS Nano. 2013 Dec 23;7(12):10704-16. doi: 10.1021/nn4035074. Epub 2013 Nov 25.

PMID:
24256569
21.

Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis.

Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM.

Leuk Res. 2012 Nov;36(11):1380-6. doi: 10.1016/j.leukres.2012.08.001. Epub 2012 Aug 24.

PMID:
22921191
22.

The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: a clinical practice guideline.

Leitch HA, Buckstein R, Shamy A, Storring JM.

Crit Rev Oncol Hematol. 2013 Feb;85(2):162-92. doi: 10.1016/j.critrevonc.2012.07.003. Epub 2012 Aug 15. Review.

PMID:
22901762
23.

Unanswered Questions in HIV Hematology.

Leitch HA, Abramson JS, Cheung MC, Hicks LK.

Adv Hematol. 2012;2012:907025. doi: 10.1155/2012/907025. Epub 2012 Jun 4. No abstract available.

24.

Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era.

Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA.

Adv Hematol. 2012;2012:910954. doi: 10.1155/2012/910954. Epub 2012 May 28.

25.

Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma.

Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, Harris M, Leitch HA.

Leuk Lymphoma. 2012 Dec;53(12):2390-6. doi: 10.3109/10428194.2012.697560. Epub 2012 Jun 18.

PMID:
22642935
26.

HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era.

Rodrigo JA, Hicks LK, Cheung MC, Song KW, Ezzat H, Leger CS, Boro J, Montaner JS, Harris M, Leitch HA.

Adv Hematol. 2012;2012:735392. doi: 10.1155/2012/735392. Epub 2011 Nov 14.

27.

Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.

Leitch HA.

Drugs. 2011 Jan 22;71(2):155-77. doi: 10.2165/11585280-000000000-00000. Review.

PMID:
21275444
28.

Controversies surrounding iron chelation therapy for MDS.

Leitch HA.

Blood Rev. 2011 Jan;25(1):17-31. doi: 10.1016/j.blre.2010.09.003. Epub 2010 Oct 27. Review.

PMID:
21030120
29.

Delineating parameters of iron overload in MDS patients treated with deferasirox.

Leitch HA.

Leuk Res. 2010 Dec;34(12):1556-7. doi: 10.1016/j.leukres.2010.06.032. Epub 2010 Aug 17. No abstract available.

PMID:
20719382
30.

Excessive neurotoxicity with ABVD when combined with protease inhibitor-based antiretroviral therapy in the treatment of AIDS-related Hodgkin lymphoma.

Cheung MC, Hicks LK, Leitch HA.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):E22-5. doi: 10.3816/CLML.2010.n.025.

PMID:
20371439
31.

Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome.

Badawi MA, Vickars LM, Chase JM, Leitch HA.

Adv Hematol. 2010;2010:164045. doi: 10.1155/2010/164045. Epub 2010 Mar 23.

32.

Iron chelation therapy in MDS: does it improve survival?

Leitch HA.

Leuk Res. 2010 Jul;34(7):852-3. doi: 10.1016/j.leukres.2010.03.005. Epub 2010 Mar 25. No abstract available.

PMID:
20346508
33.

Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?

Leitch HA, Vickars LM.

Hematology Am Soc Hematol Educ Program. 2009:664-72. doi: 10.1182/asheducation-2009.1.664. Review.

PMID:
20008252
34.

Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy.

Leitch HA, Chase JM, Goodman TA, Ezzat H, Rollins MD, Wong DH, Badawi M, Leger CS, Ramadan KM, Barnett MJ, Foltz LM, Vickars LM.

Hematol Oncol. 2010 Mar;28(1):40-8. doi: 10.1002/hon.902.

PMID:
19557769
35.

Acute leukemia in patients sixty years of age and older: a twenty year single institution review.

Leger CS, Leitch HA, Galbraith PF, Li CH, Vickars LM.

Am J Clin Oncol. 2009 Apr;32(2):137-41. doi: 10.1097/COC.0b013e31818a6c93.

PMID:
19307947
36.

Treatment of relapsed and refractory myeloma.

Reece DE, Leitch HA, Atkins H, Voralia M, Canning LA, LeBlanc R, Belch AR, White D, Kovacs MJ.

Leuk Lymphoma. 2008 Aug;49(8):1470-85. doi: 10.1080/10428190802064941. Review.

PMID:
18608859
37.
38.

Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.

Ezzat H, Filipenko D, Vickars L, Galbraith P, Li C, Murphy K, Montaner JS, Harris M, Hogg RS, Vercauteren S, Leger CS, Zypchen L, Leitch HA.

HIV Clin Trials. 2007 May-Jun;8(3):132-44.

PMID:
17621460
39.

Clinical progression and outcome of patients with monoclonal B-cell lymphocytosis.

Fung SS, Hillier KL, Leger CS, Sandhu I, Vickars LM, Galbraith PF, Li CH, Leitch HA.

Leuk Lymphoma. 2007 Jun;48(6):1087-91.

PMID:
17577771
40.

Physician perceptions and preferences in the treatment of acquired immunodeficiency syndrome (AIDS)-related lymphoma.

Cheung MC, Imrie KR, Leitch HA, Park-Wyllie LY, Buckstein R, Antoniou T, Loutfy MR.

Ann Hematol. 2007 Sep;86(9):631-8. Epub 2007 Mar 20.

PMID:
17372734
41.

Vaccine therapy for non-Hodgkin's lymphoma and other B-cell malignancies.

Leitch HA, Connors JM.

Curr Opin Investig Drugs. 2005 Jun;6(6):597-604. Review.

PMID:
15988911
42.

Rapid determination of Epstein-Barr virus latent or lytic infection in single human cells using in situ hybridization.

Leenman EE, Panzer-Grümayer RE, Fischer S, Leitch HA, Horsman DE, Lion T, Gadner H, Ambros PF, Lestou VS.

Mod Pathol. 2004 Dec;17(12):1564-72.

43.

Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases.

Lester R, Li C, Phillips P, Shenkier TN, Gascoyne RD, Galbraith PF, Vickars LM, Leitch HA.

Leuk Lymphoma. 2004 Sep;45(9):1881-5.

PMID:
15223650
44.

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis.

Mangel J, Leitch HA, Connors JM, Buckstein R, Imrie K, Spaner D, Crump M, Pennell N, Boudreau A, Berinstein NL.

Ann Oncol. 2004 Feb;15(2):283-90.

PMID:
14760123
45.

Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor.

Kuruvilla J, Leitch HA, Vickars LM, Galbraith PF, Li CH, Al-Saab S, Naiman SC.

Eur J Haematol. 2003 Nov;71(5):396-8. Erratum in: Eur J Haematol. 2004 Apr;72(4):306.

PMID:
14667206
46.

Limited-stage mantle-cell lymphoma.

Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM.

Ann Oncol. 2003 Oct;14(10):1555-61.

PMID:
14504058
47.

Necrotizing fasciitis secondary to group A streptococcus. Morbidity and mortality still high.

Leitch HA, Palepu A, Fernandes CM.

Can Fam Physician. 2000 Jul;46:1460-6. Review.

49.

Stimulation of leukemic myelopoiesis by P30-35 CAMAL, an inhibitor of normal myelopoiesis.

Leitch HA, Buskard N, Levy JG.

Leukemia. 1993 Sep;7(9):1394-401.

PMID:
8371590
50.

Inhibition of murine hematopoiesis by CAMAL, an inhibitor of human hematopoiesis.

Leitch HA, Yip ST, Jamieson CH, Levy JG.

Leukemia. 1993 May;7(5):717-24.

PMID:
8483324

Supplemental Content

Loading ...
Support Center